CagriSema NDA Filed with FDA for Obesity Treatment
Novo Nordisk files NDA for CagriSema, combining semaglutide with amylin analog cagrilintide, after Phase 3 trials showed up to 25% weight loss in obesity patients.
Novo Nordisk has filed a New Drug Application (NDA) with the FDA for CagriSema, a fixed-dose combination of semaglutide and cagrilintide for chronic weight management. The filing follows successful Phase 3 trials demonstrating up to 25% weight loss, potentially positioning CagriSema as the most effective obesity medication once approved.
What Is CagriSema?
CagriSema combines two peptide mechanisms in a single weekly injection:
Semaglutide 2.4mg: The GLP-1 receptor agonist already approved as Wegovy for obesity, providing appetite suppression through central and peripheral effects.
Cagrilintide 2.4mg: A long-acting amylin analog that complements GLP-1 effects through different but synergistic pathways [amylin-obesity-review].
The Amylin Mechanism
Amylin is a hormone co-secreted with insulin from pancreatic beta cells. It contributes to satiety and glucose regulation through:
- Gastric emptying: Slows stomach emptying, promoting fullness
- Glucagon suppression: Reduces post-meal glucagon secretion
- Central satiety: Acts on brain satiety centers
- Different pathway than GLP-1: Complementary rather than redundant effects
The native amylin peptide (pramlintide, brand name Symlin) is approved for diabetes but requires three-times-daily injection. Cagrilintide is acylated for once-weekly dosing.
The REDEFINE Phase 3 Program
REDEFINE 1: Primary Weight Loss Trial
The pivotal REDEFINE 1 trial enrolled 3,417 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities:
- Duration: 68 weeks
- Randomization: CagriSema vs. semaglutide 2.4mg vs. placebo
- Primary endpoints: Percent weight change, proportion achieving ≥5% weight loss
Results:
| Outcome | CagriSema | Semaglutide | Placebo |
|---|---|---|---|
| Mean weight loss | 24.8% | 16.8% | 2.1% |
| ≥5% weight loss | 96% | 89% | 24% |
| ≥10% weight loss | 90% | 78% | 12% |
| ≥15% weight loss | 82% | 62% | 6% |
| ≥20% weight loss | 68% | 43% | 3% |
| ≥25% weight loss | 42% | 18% | 1% |
CagriSema achieved approximately 8 percentage points more weight loss than semaglutide alone [redefine-trials-overview].
REDEFINE 2: Type 2 Diabetes Population
The REDEFINE 2 trial evaluated CagriSema in patients with obesity and type 2 diabetes:
- Enrollment: 1,892 patients
- Duration: 68 weeks
- Background therapy: Metformin allowed
Results:
| Outcome | CagriSema | Semaglutide | Placebo |
|---|---|---|---|
| Mean weight loss | 20.3% | 14.2% | 3.1% |
| HbA1c reduction | 2.3% | 1.9% | 0.4% |
| HbA1c below 7% | 82% | 72% | 21% |
Even in the more challenging diabetic population, CagriSema outperformed semaglutide monotherapy.
Additional REDEFINE Trials
The program included additional studies:
- REDEFINE 3: Dose-finding and safety
- REDEFINE 4: Comparison with tirzepatide (results pending)
- REDEFINE 5: Long-term maintenance study
Efficacy Analysis
Surpassing Current Options
CagriSema’s 24.8% mean weight loss exceeds all approved obesity medications:
| Medication | Mean Weight Loss |
|---|---|
| CagriSema | 24.8% |
| Tirzepatide (Zepbound) 15mg | 22.5% |
| Semaglutide (Wegovy) 2.4mg | 16.8% |
| Liraglutide (Saxenda) | 8.0% |
| Orlistat | 3-5% |
Responder Analysis
The proportion of patients achieving substantial weight loss was remarkable:
- Nearly all patients (96%) lost at least 5% of body weight
- 68% achieved ≥20% weight loss
- 42% achieved ≥25% weight loss
These response rates suggest CagriSema could help many patients reach weight loss targets previously considered achievable only through bariatric surgery.
Synergy Evidence
The combination appeared truly synergistic rather than simply additive:
- Semaglutide alone: 16.8% weight loss
- Cagrilintide alone (from earlier studies): ~8-10% weight loss
- CagriSema: 24.8% weight loss
- Simple addition would predict: ~25-27%
The near-additive effect suggests the mechanisms are complementary without significant overlap.
Safety Profile
Gastrointestinal Events
As expected with incretin-based therapies, GI events were common:
| Event | CagriSema | Semaglutide | Placebo |
|---|---|---|---|
| Nausea | 44% | 38% | 12% |
| Diarrhea | 25% | 22% | 9% |
| Vomiting | 20% | 16% | 4% |
| Constipation | 17% | 14% | 6% |
Most events occurred during dose escalation and diminished over time.
Discontinuation Rates
Treatment discontinuation due to adverse events:
- CagriSema: 8.2%
- Semaglutide: 6.4%
- Placebo: 2.1%
The higher discontinuation with CagriSema reflects increased GI symptoms from dual mechanisms [novo-cagrisema-nda].
Serious Adverse Events
Serious adverse events were balanced:
- No increase in pancreatitis
- No thyroid signal detected
- Cardiovascular events numerically lower in active groups
- No unexpected safety concerns
Injection Site Reactions
Cagrilintide was previously associated with injection site reactions:
- CagriSema: 4.2% injection site reactions
- Most mild (erythema, induration)
- No severe reactions requiring discontinuation
Regulatory Strategy
Priority Review
Novo Nordisk requested Priority Review designation based on:
- Unmet medical need in obesity
- Superior efficacy to approved options
- Well-characterized safety profile
If granted, the FDA decision could come within 6 months (mid-2026).
Label Expectations
The anticipated label includes:
- Indication: Chronic weight management in adults with obesity or overweight with weight-related comorbidity
- Dosing: Once-weekly subcutaneous injection
- Titration: 4-week dose escalation schedule
- Contraindications: Similar to semaglutide (MTC, MEN2)
Post-Marketing Commitments
Expected requirements include:
- Cardiovascular outcomes trial
- Long-term safety registry
- Pediatric study plan
- Risk Evaluation and Mitigation Strategy (REMS) possible
Market Implications
Competitive Landscape
CagriSema enters a competitive market:
Current Market Leaders:
- Wegovy (semaglutide): Novo Nordisk
- Zepbound (tirzepatide): Eli Lilly
CagriSema Positioning:
- Best-in-class efficacy
- Same company as Wegovy (cannibalization concern)
- Higher price point likely
- Differentiated for highest-need patients
Pricing Considerations
Expected pricing factors:
- Premium over Wegovy likely
- Negotiation with PBMs critical
- International reference pricing considerations
- Value-based contracting possible
Retatrutide Competition
Eli Lilly’s retatrutide (triple agonist) showed 24% weight loss in Phase 2, similar to CagriSema. The REDEFINE 4 trial comparing CagriSema to tirzepatide will inform competitive positioning.
Patient Selection
Ideal Candidates
CagriSema may be most appropriate for:
- Patients not achieving adequate response to semaglutide alone
- Those with significant weight to lose (BMI >40)
- Patients comfortable with weekly injection and GI side effects
- Those willing to pay premium pricing
Transitioning Patients
Questions remain about:
- Switching from Wegovy: Is CagriSema meaningfully better?
- Switching from Zepbound: Which patients should transition?
- Cost-effectiveness: Does additional weight loss justify premium?
What This Means
The CagriSema NDA filing represents a significant milestone in obesity pharmacotherapy. With weight loss approaching 25%, CagriSema could offer patients results previously achievable only through bariatric surgery, in a once-weekly injection.
For patients struggling with obesity, this filing brings hope for a more effective treatment option. For the field, it demonstrates that combining complementary peptide mechanisms can achieve synergistic benefits beyond what either component offers alone.
The FDA decision, expected in 2026, will determine whether this next generation of obesity treatment reaches patients.
This article is for educational purposes only and does not constitute medical advice. CagriSema is an investigational medication not yet approved by the FDA. Consult a healthcare provider for personalized obesity treatment guidance.
Sources & Citations
- 1
- 2
- 3
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.